相关实验视频
Updated: Jun 25, 2025

03:26
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
Published on: August 28, 2020
2.0K
准则的指导方针:神经性下尿道功能障碍的保守,药理和外科治疗
Diana Carolina Ochoa1, Alessia Christina Mahoney2, Christina Fontaine3
1Department of Bristol Urological Institute, Southmead Hospital, Bristol, UK.
Urology research & practice
|May 27, 2024
概括
管理神经性下尿路功能障碍 (NLUTD) 涉及各种指导建议. 这项研究综合了保守,药理和手术选择,以帮助临床决策,以获得更好的患者结果.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 神经学 神经学
- 临床指南 临床指南
背景情况:
- 神经性下尿路功能障碍 (NLUTD) 提出了各种临床挑战.
- 有效的治疗对于保持功能和改善患者生活质量至关重要.
- 现有的临床指南提供了不同的建议,因为高质量的证据有限.
研究的目的:
- 通过突出的国际指南,审查和综合NLUTD的管理策略.
- 为了比较和对比保守,药物和手术干预的建议.
- 为管理NLUTD的医疗保健专业人员提供综合概述.
主要方法:
- 系统审查著名的NLUTD临床指南.
- 推的管理选项的比较分析.
- 支持不同治疗方式的证据摘要.
主要成果:
- 对于NLUTD管理的指导方针建议存在显著差异.
- 保守的,药物和手术选择显示不同程度的证据和支持.
- 显然,需要基于强有力的临床证据制定协调一致的建议.
结论:
- 目前的NLUTD指南在管理策略中存在差异.
- 综合这些指导方针有助于导航治疗选择.
- 需要进一步的研究,以建立基于证据的共识,以获得最佳的NLUTD护理.
相关概念视频
Irritable Bowel Syndrome III: Medical and Nursing Management
195
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
195
The Micturition Reflex
567
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
567
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Peptic Ulcer Disease V: Surgical Management and Nursing Care
292
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
292
Drugs for Treatment of Diarrhea-Predominant IBS
160
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
160

